First Time Loading...

ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 28.2 TWD 0.89% Market Closed
Updated: Apr 25, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
ScinoPharm Taiwan Ltd

Wall Street analysts forecast ScinoPharm Taiwan Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ScinoPharm Taiwan Ltd is 27 TWD .

Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
27 TWD
4% Downside
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
27 TWD
4% Downside
Highest
Price Target
Not Available
ScinoPharm Taiwan Ltd Competitors:
Price Targets
B
003850
Boryung Corp
58% Upside
300026
Tianjin Chase Sun Pharmaceutical Co Ltd
474% Upside
I
ITCI
Intra-Cellular Therapies Inc
27% Upside
AVDL
Avadel Pharmaceuticals PLC
36% Upside
B
003850
Boryung Corp
58% Upside
300026
Tianjin Chase Sun Pharmaceutical Co Ltd
474% Upside
I
ITCI
Intra-Cellular Therapies Inc
27% Upside
AVDL
Avadel Pharmaceuticals PLC
36% Upside
HYPE3
Hypera SA
57% Upside
4554
Fuji Pharma Co Ltd
38% Upside
DMP
Dermapharm Holding SE
86% Upside
M
4016
Middle East Pharmaceutical Industries Company SJSC
25% Downside

Revenue
Forecast

Revenue Estimate
ScinoPharm Taiwan Ltd

For the last 8 years the compound annual growth rate for ScinoPharm Taiwan Ltd's revenue is -3%. The projected CAGR for the next 1 year is -5%.

-3%
Past Growth
-5%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
ScinoPharm Taiwan Ltd

For the last 8 years the compound annual growth rate for ScinoPharm Taiwan Ltd's operating income is -10%. The projected CAGR for the next 1 year is -33%.

-10%
Past Growth
-33%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
ScinoPharm Taiwan Ltd

For the last 8 years the compound annual growth rate for ScinoPharm Taiwan Ltd's net income is -9%. The projected CAGR for the next 1 year is -27%.

-9%
Past Growth
-27%
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ScinoPharm Taiwan Ltd's stock price target?
Price Target
27 TWD

According to Wall Street analysts, the average 1-year price target for ScinoPharm Taiwan Ltd is 27 TWD .

What is ScinoPharm Taiwan Ltd's Revenue forecast?
Projected CAGR
-5%

For the last 8 years the compound annual growth rate for ScinoPharm Taiwan Ltd's revenue is -3%. The projected CAGR for the next 1 year is -5%.

What is ScinoPharm Taiwan Ltd's Operating Income forecast?
Projected CAGR
-33%

For the last 8 years the compound annual growth rate for ScinoPharm Taiwan Ltd's operating income is -10%. The projected CAGR for the next 1 year is -33%.

What is ScinoPharm Taiwan Ltd's Net Income forecast?
Projected CAGR
-27%

For the last 8 years the compound annual growth rate for ScinoPharm Taiwan Ltd's net income is -9%. The projected CAGR for the next 1 year is -27%.

ALPHA SPREAD
Join more than 131,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.